Trials / Recruiting
RecruitingNCT06382103
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 240 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ctDNA monitoring | The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay. |
| DIAGNOSTIC_TEST | Plasma proteomic analysis | plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis |
Timeline
- Start date
- 2024-05-15
- Primary completion
- 2025-05-20
- Completion
- 2026-05-20
- First posted
- 2024-04-24
- Last updated
- 2025-03-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06382103. Inclusion in this directory is not an endorsement.